- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Begendina&rg; (proprietary name) | BT 5/9 | SAND 26
Compound class: Antibody
Comment: Begelomab is an investigational murine monoclonal antibody targeting DPP4 (dipeptidyl-peptidase 4, a.k.a. CD26 T cell antigen).
Peptide sequence and structural information for begelomab is available from its IMGT/mAb-DB entry.
A search of patent literature reveals that the heavy chain variable region CDRs and light chain variable region CDRs of begelomab match sequences of anti-CD26 antibodies disclosed in FIG 2a of patent EP2767549 A1 .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Begelomab is a DPP4 (CD26)-targeting monoclonal antibody that was in Phase 3 clinical trial vs. conventional second-line treatment for steroid-resistant GvHD (see NCT02411084). The study appears to have been terminated on grounds of insufficient rate of participant recriutment. Mechanistically the antibody targets activated CD26+ T cells that appear to accumulate in the organs of patients with GvHD.|
|Graft versus host disease||Ex Phase 3 clinical candidate for steroid-resistant GvHD- see NCT02411084.|